Broncus LungPoint

Dec 9, 2009

This video demonstrates fiber-optic bronchoscopy image (left) with virtual bronchoscopy image (right). Colored lines indicate pathways to target calculated by LungPoint software. Video supplied by Broncus Technologies.

none
Latest in Home
Representative axial images of mild, moderate, and severe emphysema at baseline low-dose CT (LDCT). Participants were categorized as having no emphysema or mild, moderate, or severe emphysema. When present, emphysema was mild if no distinct regions of reduced attenuation were visible on the CT scan, but vascular splaying indicates parenchymal expansion, or if only occasional discrete low-attenuation regions were observed. Moderate emphysema was defined by the presence of identifiable low-attenuation regions affecting less than half of the lung parenchyma, whereas severe emphysema was defined by the presence of identifiable low-attenuation regions that involved more than half of the lung parenchyma. A scoring system from 0 to 3 was applied, corresponding to none, mild, moderate, and severe emphysema, respectively. Yellow circle indicates the extent of emphysema. (A) A 67-year-old man with mild emphysema at baseline LDCT in 2002. Baseline LDCT scan shows vascular splaying, suggesting parenchymal expansion due to emphysema and occasional discrete low-attenuation regions. The participant ultimately died of cardiovascular disease 15.4 years (184.2 months) later. (B) A 69-year-old man with moderate emphysema at baseline LDCT in 2007. The participant died of cardiovascular disease 1.8 years (21.9 months) later. Identifiable low-attenuation regions affected less than half of the lung parenchyma. (C) An 85-year-old woman with severe emphysema at baseline LDCT in 2006. After 5.5 years (65.5 months) of follow-up, the participant died due to chronic obstructive pulmonary disease–related causes. Identifiable low-attenuation regions involved more than half of the lung parenchyma.
Low-dose CT ties emphysema to mortality in previous smokers
September 9, 2025
"Join Us"
Sponsored
"Join Us"
September 3, 2025
Mri Scan Brain
Neuroradiology still lacks gender, racial/ethnic diversity
September 8, 2025
Bayer Thumbnail
Bayer pivots away from AI platform business
September 8, 2025
More in Home
Low-dose CT ties emphysema to mortality in previous smokers
By Amerigo Allegretto
Study findings highlight the clinical relevance of CT-diagnosed emphysema.
September 9, 2025
Representative axial images of mild, moderate, and severe emphysema at baseline low-dose CT (LDCT). Participants were categorized as having no emphysema or mild, moderate, or severe emphysema. When present, emphysema was mild if no distinct regions of reduced attenuation were visible on the CT scan, but vascular splaying indicates parenchymal expansion, or if only occasional discrete low-attenuation regions were observed. Moderate emphysema was defined by the presence of identifiable low-attenuation regions affecting less than half of the lung parenchyma, whereas severe emphysema was defined by the presence of identifiable low-attenuation regions that involved more than half of the lung parenchyma. A scoring system from 0 to 3 was applied, corresponding to none, mild, moderate, and severe emphysema, respectively. Yellow circle indicates the extent of emphysema. (A) A 67-year-old man with mild emphysema at baseline LDCT in 2002. Baseline LDCT scan shows vascular splaying, suggesting parenchymal expansion due to emphysema and occasional discrete low-attenuation regions. The participant ultimately died of cardiovascular disease 15.4 years (184.2 months) later. (B) A 69-year-old man with moderate emphysema at baseline LDCT in 2007. The participant died of cardiovascular disease 1.8 years (21.9 months) later. Identifiable low-attenuation regions affected less than half of the lung parenchyma. (C) An 85-year-old woman with severe emphysema at baseline LDCT in 2006. After 5.5 years (65.5 months) of follow-up, the participant died due to chronic obstructive pulmonary disease–related causes. Identifiable low-attenuation regions involved more than half of the lung parenchyma.
AI boosts cardiac PET imaging
By Will Morton
AI-enhanced rubidium-82 myocardial blood flow imaging matched the quality of F-18 flurpiridaz PET perfusion imaging.
September 8, 2025
2025 09 08 Mpi Ai Thumbnail
Neuroradiology still lacks gender, racial/ethnic diversity
By Amerigo Allegretto
Despite efforts, national data show that gender and racial/ethnic disparities persist in neuroradiology.
September 8, 2025
Mri Scan Brain
Bayer pivots away from AI platform business
By Erik L. Ridley
Bayer is discontinuing its Calantic Digital Solutions platform as well as products and services from its Blackford Analysis subsidiary.
September 8, 2025
Bayer Thumbnail
PET use increasing in diagnosing cardiac device infections
By Will Morton
Integrating F-18 FDG-PET into standardized diagnostic protocols could enhance early detection of cardiac device-related infections.
September 5, 2025
Hand Touching Heart Hologram Stock Have A Nice Day Thumbnail
ISCT: CT is an ideal imaging modality for cardiometabolic screening
By Kate Madden Yee
Tracking biomarkers on CT could help clinicians better predict patient outcomes.
September 5, 2025
Ct Scanner Control Room2 Radiologist
ISCT: Radiologists can help reduce iodinated contrast media waste
By Amerigo Allegretto
Radiologists can take proactive measures in reducing iodinated contrast media waste, according to an ISCT presentation.
September 5, 2025
Wastewater Treatment
ISCT: Mayo Clinic expert outlines how best to allocate PCCT resources
By Liz Carey
A Mayo Clinic radiologist discusses overcoming photon-counting CT (PCCT) operational challenges.
September 5, 2025
2025 09 05 Isct Temporal Bone Ossicular Impact Pcct Imaging Thumbnail
PET tracer shows promise in patients with neuroblastoma
By Will Morton
The PET tracer performed better than standard SPECT imaging with iodine-123 metaiodobenzylguanidine.
September 4, 2025
I-123 MIBG–negative and F-18 MFBG–positive scans showing multiple lesions in 9-year-old male with relapsed high-risk, multiple-relapse neuroblastoma (stage IV disease) receiving chemoimmunotherapy. (A) I-123 MIBG uptake is seen in lower lumbar vertebrae (arrows). Positive uptake with F-18 MFBG PET (B; black arrows) in skull, spine, pelvic bones, femora, and left tibia (B and C; blue and white arrows). Bone marrow biopsy was positive for disease. Follow-up I-123 MIBG imaging (D; left) and spine MRI (D; right) performed six weeks later showed diffuse disease in skull and spine, corresponding to F-18 MFBG–avid sites.
ISCT: 2022 ICM shortage was a 'wake-up call.' Did we listen?
By Kate Madden Yee
In 2022, the global supply chain for ICM was disrupted by COVID lockdowns -- and this kind of crisis will likely occur again.
September 4, 2025
Contrast Injector
Radiology world mourns death of Leonard Berlin
By Amerigo Allegretto
The radiology world is mourning the death of Leonard Berlin, MD, a leading voice on the intersection between medicine and malpractice.
September 4, 2025
Flower Chrysanthemum 400
Revealed: The cause of CT safety incident in Belgium
By Edna Astbury-Ward, PhD
A single bottle of contaminated contrast agent was the cause of eight patients' illness after undergoing CT in Belgium.
September 4, 2025
Klebsiella Adobe Zachary
Page 1 of 168
Next Page